China SXT Pharmaceuticals (NASDAQ:SXTC) Shares Down 11.3% – Here’s Why

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares were down 11.3% during mid-day trading on Tuesday . The company traded as low as $2.33 and last traded at $2.36. Approximately 119,446 shares traded hands during trading, a decline of 93% from the average session volume of 1,637,487 shares. The stock had previously closed at $2.66.

Wall Street Analyst Weigh In

Several analysts recently weighed in on SXTC shares. Weiss Ratings downgraded China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, August 31st. Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, August 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

China SXT Pharmaceuticals Stock Down 11.3%

The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $47.12 and a two-hundred day simple moving average of $116.58.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings results on Wednesday, July 1st. The company reported $6.84 earnings per share (EPS) for the quarter. The company had revenue of $0.26 million during the quarter.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.